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mately 30% of total costs. Effective oral therapies for treatment
of breast cancer could help offset some of these costs in addition
to providing patient beneﬁts such as fewer clinic visits for IV
administration.
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OBJECTIVES: Since accurate tumor localization during radio-
therapy is critical to maximizing therapeutic efﬁcacy while 
minimizing toxicity, the cost-effectiveness of localization tech-
nologies should be investigated. We performed a cost-utility
analysis evaluating the relative advantage of using a real-time 4D
electromagnetic tracking system, the Calypso® 4D Localization
System with Beacon® Transponders (“Calypso® 4D Localiza-
tion System;” Calypso Medical, Seattle, Washington) during
prostate radiotherapy. METHODS: Using decision analysis and
Markov processes, the outcomes of patients localized during
prostate radiotherapy were simulated over ﬁve years and mea-
sured as direct costs from a payer’s perspective and quality-
adjusted life years (QALYs). The clinical pathway for patients
undergoing external beam radiation was modeled via health
states: 1) Time in Treatment, 2) Relapse-Free with Localization,
3) Relapse-Free without Localization, and 4) Deceased. Using
evidence from a prospective clinical trial of the Calypso® 4D
Localization System and published literature, transition states
were modeled for achievement of biochemical no evidence of
disease (bNED) control and biochemical relapse-free survival
(BRFS). Costs and disutilities of radiation-induced toxicities
were included. Post-hoc sensitivity analyses were performed.
RESULTS: Over ﬁve years, patients localized with real-time 4D
electromagnetic tracking gained 2.47 QALYs at $5432/QALY.
Compared to ultrasound, electronic portal imaging devices, or
computed tomography, the real-time 4D electromagnetic track-
ing system yielded superior QALY gains at comparable costs.
Compared to ultrasound, this technology generated 43 addi-
tional quality-adjusted life days and an incremental cost-
effectiveness ratio of $14,053/QALY. Overall, the model was
sensitive to changes in bNED control rates and BRFS. CON-
CLUSION: The real-time 4D electromagnetic tracking system is
cost-effective for target localization during prostate radiother-
apy. However, the current model’s sensitivity to variances in
long-term outcomes warrants collection of rigorous evidence on 
long-term quality of life and tumor control in patients using
localization technologies. Future studies might incorporate
patient registry data, patient-reported outcomes, and follow-up
data from prospective clinical trials.
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OBJECTIVES: Renal cancer represents 1.5% of all tumors
observed in Mexico and they are responsible of high expendi-
tures in the Mexican Health System. The purpose of the study
was to model the economic and health consequences of second-
line treatments (previous failure of cytokine therapies) in adult
patients with metastatic renal cell carcinoma (mRCC) in stages
III and IV from the health care payer’s perspective. METHODS:
A cost—utility analysis was developed using a Markov model-
ing approach. The model simulates costs and quality adjusted
life years (QALYs) gained in a ten-year period among four pos-
sible health states (no new progression, death due to mRCC,
history of new progression and death due to other causes). The
model aimed to compare sunitinib 50 mg/day vs. local best sup-
portive care (BSC) as second-line treatments. Transition prob-
abilities and QALYs of the Markov model were obtained
according to clinical trials previously published in the literature.
Resource use and costs data was obtained from hospital records
at Hospital de Oncología CMN “Siglo XXI” in Mexico City (n
= 80). Both costs and QALYs were discounted using a 5% annual
rate. Probabilistic sensitivity analysis was performed and
tornado diagrams were constructed (±25% on relevant model
variables). RESULTS: Second line treatment with sunitinib
showed the highest QALYs gained per patient (1.32 QALYs) vs.
BSC treatment (0.39 QALYs). Nevertheless, expected health care
costs for sunitinib resulted in US$36,928 and BSC therapies in
US$4103. The incremental cost per QALY gained resulted in
US$35,238. Results were robust to Monte Carlo ﬁrst order sen-
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